Abstract
BackgroundThe oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) erlotinib is an established second-line treatment for advanced non-small cell lung cancer (NSCLC). Erlotinib delays disease progression and increases...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have